|
|
|
| 新型ER拮抗剂AZD9496对ER阳性肿瘤细胞的抑制作用 |
| 胡梦琪,李昭,李劼 |
| 湖南师范大学第一附属医院/湖南省人民医院妇产科,湖南 长沙 410000 |
|
|
|
|
摘要 【目的】探讨新型雌激素受体(ER)拮抗剂AZD9496对ER阳性(ER+)肿瘤细胞的抑制作用。【方法】体外培养ER+乳腺癌细胞MCF-7、子宫内膜癌细胞RL95-2和卵巢癌细胞OVCAR-3,各细胞经100 nM 17β-estradiol (E2)诱导增殖后采用CellTiter-Glo发光法检测不同浓度的ER拮抗剂AZD9496作用于诱导后的ER+肿瘤细胞24 h、48 h、72 h的活力变化,采用In cell western检测ER蛋白的表达水平。【结果】AZD9496抑制ER+的MCF-7、RL95-2、OVCAR-3肿瘤细胞增殖,且呈时间及剂量依赖性。In cell western结果显示,随着药物AZD9496浓度增加,ER蛋白表达水平逐渐减少。【结论】AZD9496可抑制ER+肿瘤细胞增殖能力,并降低其ER蛋白表达水平,其可应用于临床治疗ER+肿瘤。
|
|
| 关键词 ：
AZD9496,
雌激素依赖型肿瘤,
雌激素受体
|
|
收稿日期: 2017-12-08
|
|
|
[1] Weir HM,Bradbury RH,Lawson M,et al.AZD9496:an oral estrogen receptor inhibitor that blocks the growth of er-positive and esr1-mutant breast tumors in preclinical models[J].Cancer Res,2016,76(11):3307-3318.
[2] Vanderstichele A,Neven P,Vergote I.Combined modality adjuvant therapy for high-risk endometrial cancer[J].Lancet Oncol,2016,17(8):1029-1030.
[3] Rose PG.Endometrial carcinoma[J].N Engl J Med,1996,335(9):640-649.
[4] Morice P,Leary A,Creutzberg C,et al.Endometrial cancer[J].Lancet,2016,387(10023):1094-1108.
[5] Poorolajal J,Nafissi N,Akbari ME,et al.Breast cancer survival analysis based on immunohistochemistry subtypes (er/pr/her2):a retrospective cohort study[J].Arch Iran Med,2016,19(10):680-686.
[6] Sieh W,Kobel M,Longacre TA,et al.Hormone-receptor expression and ovarian cancer survival:an ovarian tumor tissue analysis consortium study[J].Lancet Oncol,2013,14(9):853-862.
[7] Arafa M,Somja J,Dehan P,Kridelka F,et al.Current concepts in the pathology and epigenetics of endometrial carcinoma[J].Pathology,2010,42(7):613-617. |
|
|
|
2018, Vol. 35 
